No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.

Mild and reversible AKI was tied to an increased risk for probable dementia and mild cognitive impairment in older adults ...

CKD can lead to severe complications like anemia, uremic gastroenteritis, and renal secondary hyperparathyroidism. Early ...

including renal replacement therapy (RRT) when necessary. One of the critical areas of research is the relationship between sepsis and AKI. Sepsis-associated acute kidney injury (SA-AKI ...

The use of standardized definitions, such as the neonatal modified Kidney Disease: Improving Global Outcomes (KDIGO) criteria, has improved the ability to identify and study AKI in neonates ...

The use of SGLT2 vs DPP4 inhibitors was linked to reduced cardiovascular and renal risks among patients with comorbid SLE and T2D.

“We look forward to the results and plan to educate the public over the next few months on the importance of the planned biomarkers as it relates to CKD treatment and prevention of AKI.

Mayo Clinic has joined SeaStar Medical as the 15th site authorised to enrol subjects for the company’s pivotal NEUTRALIZE-AKI ...

In keeping with current guidelines, either empagliflozin or dapagliflozin can be used for preventing AKI and CKD in patients with type 2 diabetes. Empagliflozin and dapagliflozin are equally ...